Darren Charlton Smith
CIK: 0002122447
Transaction Breakdown
Open Market Buys (P)1 (50.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)1 (50.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
TLX
Telix Pharmaceuticals Ltd
Officer
Discretionary Trading P&L
Holdings
About Smith Darren Charlton
Smith Darren Charlton (SEC CIK 0002122447) files insider reports with the SEC as Group Chief Financial Officer of Telix Pharmaceuticals Ltd (TLX).
Signal8 holds 3 ownership filings by Smith Darren Charlton (1 Form 3, 2 Form 4), filed between Apr 1, 2026 and Sep 14, 2026. Those filings report 2 transactions, from Mar 29, 2026 to Sep 7, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith Darren Charlton's filings is in NORTH MELBOURNE.
Recent filings by Smith Darren Charlton
Other insiders filing for Telix Pharmaceuticals Ltd (TLX)
- GILL DAVID N, Director
- Jellison William R, Director
- Rivas Maria, Director
- Behrenbruch Christian, MD & Group CEO
- Cade David Norman, Group Chief Medical Officer
- Nelson Mark Alexander, Director